Log In
BCIQ
Print this Print this
 

AP-1531

  Manage Alerts
Collapse Summary General Information
Company BTG plc
DescriptionProstaglandin E2 (PGE2) receptor EP4 subtype (Prostanoid EP4 receptor; PTGER4) antagonist
Molecular Target Prostaglandin E2 (PGE2) receptor EP4 subtype (Prostanoid EP4 receptor) (PTGER4)
Mechanism of ActionProstaglandin E2 receptor EP4 antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMigraine
Indication DetailsTreat acute migraine attacks
Regulatory Designation
PartnerAriel Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/26/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today